Neonatal Lupus: Clinical Manifestations and Treatment Options

Neonatal systemic lupus erythematosus syndrome develops as a result of passively acquired autoimmunity, when autoantibodies produced by the mother cross the placenta, affecting the developing ...

Identifying SLE-Related Health Demands Using Data Mining, Big Data

"Infodemiology" and "infoveillance" are terms used to describe an emerging approach to public health research, based on Google Trends big data monitoring and data mining.

Unmet Needs in the Pathogenesis, Treatment of Systemic Lupus Erythematosus

Improved survival has ushered in new challenges that inadvertently increase the risk for death in patients with SLE.

Cardiovascular Disease Risk in Patients With Systemic Lupus Erythematosus

Improved treatment in SLE with increased life expectancy has been accompanied by an elevated risk for developing cardiovascular diseases.

Drug-Induced Lupus Erythematosus: Clinical Presentation and Differential Diagnosis

Drug-induced lupus erythematosus refers to an idiosyncratic side effect of medications with clinical features similar to the autoimmune-driven idiopathic lupus erythematosus.

Advancing Understanding of Shrinking Lung Syndrome in SLE

The diagnosis and management of shrinking lung syndrome, a rare complication of systemic lupus erythematosus, is discussed in a comprehensive review.

Optimal ANA Cutoff Titer as Entry Criterion for SLE Classification

The new approach in development proposes the use of positive indirect immunofluorescence ANA (IIF-ANA) as an entry criterion for SLE classification.

Lymphoma in Patients With Systemic Lupus Erythematosus: Expert Insights

In this expert interview, Sasha Bernatsky, MD, PhD, and Michelle Petri, MD, MPH, discuss the risk of non-Hodgkin lymphoma in SLE.

Lupus: Using Diet and Nutrition to Improve Symptoms and Outcomes

Consuming adequate amounts of the right nutrients, and limiting others, can help relieve symptoms and improve outcomes in patients with systemic lupus erythematosus.

Applying Precision Medicine to Systemic Lupus Erythematosus

Clinicians and researchers weigh in on the advent of precision medicine for the treatment of SLE.

Latest News

Assessment of Nitrated Nucleosome Levels and Neuropsychiatric Events in Systemic Lupus Erythematosus

Assessment of Nitrated Nucleosome Levels and Neuropsychiatric Events in Systemic Lupus Erythematosus

At this time, no serological test can distinguish neuropsychiatric events resulting from SLE activity from events resulting from other causes.

Association Between Maternal Systemic Lupus Erythematosus and Asthma in Offspring

Association Between Maternal Systemic Lupus Erythematosus and Asthma in Offspring

The risk for asthma may be increased in children born to mothers with systemic lupus erythematosus during pregnancy.

Comparable Risk for Atherosclerosis in Antiphospholipid Syndrome and Diabetes

Comparable Risk for Atherosclerosis in Antiphospholipid Syndrome and Diabetes

Patients with primary antiphospholipid syndrome and systemic lupus erythematosus-associated antiphospholipid syndrome have an almost 2.5-fold risk for development of atherosclerotic plaques in carotid and femoral arteries compared with healthy control patients.

Predictors of Incident Proteinuria in Systemic Lupus Erythematosus

Predictors of Incident Proteinuria in Systemic Lupus Erythematosus

Older patients with SLE are at a low risk for the development of proteinuria.

Failure to Achieve Low Disease Activity Linked to Early Damage Accrual in SLE

Failure to Achieve Low Disease Activity Linked to Early Damage Accrual in SLE

Lupus low disease activity state has been shown to be achievable and negatively associated with early damage accrual.

Consistent Antimalarial Intake in First 5 Years of SLE Linked to Improved Prognosis

Consistent Antimalarial Intake in First 5 Years of SLE Linked to Improved Prognosis

Investigators evaluated long-term outcomes with antimalarial use and organ damage, flares, disease activity, glucocorticoid use, and antimalarial associated retinopathy.

Evidence-Based Recommendations for the Diagnosis, Treatment of Childhood-Onset Lupus Nephritis

Evidence-Based Recommendations for the Diagnosis, Treatment of Childhood-Onset Lupus Nephritis

The SHARE initiative has formulated evidence-based recommendations for the diagnosis and treatment of lupus nephritis childhood-onset lupus nephritis.

Maternal Systemic Lupus Erythematosus May Increase Risk for Childhood Asthma

Maternal Systemic Lupus Erythematosus May Increase Risk for Childhood Asthma

Maternal systemic lupus erythematosus during pregnancy is associated with increased risk for asthma in children.

Switching Antimalarial Agent in Patients With Cutaneous Lupus Erythematosus

Switching Antimalarial Agent in Patients With Cutaneous Lupus Erythematosus

Switching from 1 antimalarial agent to a second may be beneficial in patients with cutaneous lupus erythematosus.

Atacicept Effective for Systemic Lupus Erythematosus Activity, Severity

Atacicept Effective for Systemic Lupus Erythematosus Activity, Severity

Atacicept may be safe and effective for lowering disease activity and severity in patients with active systemic lupus erythematosus.

Systemic Lupus Erythematosus Mortality Rates Decreased in the United States from 1968 to 2013

Systemic Lupus Erythematosus Mortality Rates Decreased in the United States from 1968 to 2013

Rates of SLE mortality have declined, but remain high relative to non-SLE mortality.

Active Nephritis in Active SLE: Identification of a New Biomarker

Active Nephritis in Active SLE: Identification of a New Biomarker

Anti-ficolin-2 autoantibodies may represent a biomarker for renal manifestations in patients with active systemic lupus erythematosus.

EULAR/ACR Systemic Lupus Erythematosus Classification Criteria Update

EULAR/ACR Systemic Lupus Erythematosus Classification Criteria Update

EULAR and ACR jointly funded and collaborated on creating a set of criteria that can be used to more accurately identify patients with SLE for inclusion in clinical trials.

Systemic Lupus Erythematous Responder Index: Primary Drivers

Systemic Lupus Erythematous Responder Index: Primary Drivers

The efficacy variables with the greatest effect on systemic lupus erythematous (SLE) Responder Index responder status in clinical trials include SLE Disease Activity Index improvement, concomitant medication adherence, and trial completion.

Anti-Ro/SSA-Positive Pregnancies and Fetal Cardiac Conduction Disturbances

Anti-Ro/SSA-Positive Pregnancies and Fetal Cardiac Conduction Disturbances

The recurrence of fetal cardiac conduction disturbances in the fetuses of women expressing anti-Ro/SSA antibodies may be influenced by the season of the year and maternal age.

Impact of Remission, Low Disease Activity on Outcomes in Lupus

Impact of Remission, Low Disease Activity on Outcomes in Lupus

While a treat to target strategy has been proposed for managing SLE, the impact of possible disease outcomes has not been fully evaluated.

Smoking May Be Linked to Pathogenesis of Anti-double Stranded DNA in SLE

Smoking May Be Linked to Pathogenesis of Anti-double Stranded DNA in SLE

Current smoking and >10 pack-years of smoking have demonstrated a strong and specific association with an increased risk for occurrence of anti-double-stranded DNA systemic lupus erythematosus.

In SLE, Medication Non-Adherence, Depression Are Prevalent

In SLE, Medication Non-Adherence, Depression Are Prevalent

In patients with SLE, 62.1% did not adhere to their medication regimens and 35% of patients demonstrated a depressed mood.

Trauma Associated With Incident Systemic Lupus Erythematosus in Women

Trauma Associated With Incident Systemic Lupus Erythematosus in Women

Identification of the biologic pathways by which psychosocial trauma may increase a woman's risk for autoimmune disorders is critical and may offer greater insight into disease etiology and strategies for prevention.

Systemic Lupus Erythematosus-Associated Cognitive Impairment May Be Identified With New Screening Tool

Systemic Lupus Erythematosus-Associated Cognitive Impairment May Be Identified With New Screening Tool

The high prevalence of cognitive impairment in patients with SLE creates a need for a reliable and cost-effective screening tool.

Sign Up for Free e-newsletters